151 related articles for article (PubMed ID: 26310369)
1. Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Park SH; Noh SJ; Kim KM; Bae JS; Kwon KS; Jung SH; Kim JR; Lee H; Chung MJ; Moon WS; Kang MJ; Jang KY
Transl Oncol; 2015 Aug; 8(4):239-49. PubMed ID: 26310369
[TBL] [Abstract][Full Text] [Related]
2. Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Kim KM; Moon YJ; Park SH; Park HJ; Wang SI; Park HS; Lee H; Kwon KS; Moon WS; Lee DG; Kim JR; Jang KY
PLoS One; 2016; 11(9):e0163193. PubMed ID: 27643881
[TBL] [Abstract][Full Text] [Related]
3. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Zhu Q; Han SX; Zhou CY; Cai MJ; Dai LP; Zhang JY
Oncotarget; 2015 May; 6(13):11575-84. PubMed ID: 25865228
[TBL] [Abstract][Full Text] [Related]
5. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Park HJ; Bae JS; Kim KM; Moon YJ; Park SH; Ha SH; Hussein UK; Zhang Z; Park HS; Park BH; Moon WS; Kim JR; Jang KY
J Exp Clin Cancer Res; 2018 May; 37(1):107. PubMed ID: 29784019
[TBL] [Abstract][Full Text] [Related]
6. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
7. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
8. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
9. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
10. Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
Wang X; Liu L; Montagna C; Ried T; Deng CX
Cell Death Differ; 2007 May; 14(5):924-31. PubMed ID: 17318223
[TBL] [Abstract][Full Text] [Related]
11. Expression of DNA repair proteins in endometrial cancer predicts disease outcome.
Mhawech-Fauceglia P; Wang D; Kim G; Sharifian M; Chen X; Liu Q; Lin YG; Liu S; Pejovic T
Gynecol Oncol; 2014 Mar; 132(3):593-8. PubMed ID: 24508840
[TBL] [Abstract][Full Text] [Related]
12. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Hybiak J; Domagala P; Domagala W
Pol J Pathol; 2018; 69(4):347-355. PubMed ID: 30786684
[TBL] [Abstract][Full Text] [Related]
14. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
Oei AL; Ahire VR; van Leeuwen CM; Ten Cate R; Stalpers LJA; Crezee J; Kok HP; Franken NAP
Int J Hyperthermia; 2018 Feb; 34(1):39-48. PubMed ID: 28540821
[TBL] [Abstract][Full Text] [Related]
15. Expression of oxidized protein tyrosine phosphatase and γH2AX predicts poor survival of gastric carcinoma patients.
Hussein UK; Park HS; Bae JS; Kim KM; Chong YJ; Kim CY; Kwon KS; Chung MJ; Lee H; Kang MJ; Moon WS; Jang KY
BMC Cancer; 2018 Aug; 18(1):836. PubMed ID: 30126387
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer.
Okada S; Tokunaga E; Kitao H; Akiyoshi S; Yamashita N; Saeki H; Oki E; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 May; 19(5):1499-507. PubMed ID: 22179631
[TBL] [Abstract][Full Text] [Related]
18. NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
Mangia A; Scarpi E; Partipilo G; Schirosi L; Opinto G; Giotta F; Simone G
Oncotarget; 2017 Sep; 8(39):65730-65742. PubMed ID: 29029467
[TBL] [Abstract][Full Text] [Related]
19. Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Ding X; Ray Chaudhuri A; Callen E; Pang Y; Biswas K; Klarmann KD; Martin BK; Burkett S; Cleveland L; Stauffer S; Sullivan T; Dewan A; Marks H; Tubbs AT; Wong N; Buehler E; Akagi K; Martin SE; Keller JR; Nussenzweig A; Sharan SK
Nat Commun; 2016 Aug; 7():12425. PubMed ID: 27498558
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.
Wang GH; Zhao CM; Huang Y; Wang W; Zhang S; Wang X
Hum Pathol; 2018 Jan; 71():135-144. PubMed ID: 29126833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
